Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Other hematologic neoplasm 3Myeloid 2Lymphoid 2Dermatologic 2CNS 2Classical hematology 1

Conditions

Melanoma 2

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Muromonab-CD3 × Dermatologic × Clear all
NCT00004022 2013-04-05

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
Dermatologic

Melanoma

NCT00080353 2012-06-14

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡